AD-5423, a D(2)/5-HT2 antagonist, is in phase II clinical trials by Dainippon for the treatment of schizophrenia and other psychoses. In a phase I study of AD-5423 in eight healthy volunteers, it appeared to be well-tolerated and failed to induce extra pyramid... ...
